The pathogenesis of amyloidosis in periodic disease: Some aspects
https://doi.org/10.17650/1818-8338-2012-3-4-62-66
Abstract
Sufficient information indicating the implication of dysfunction of interleukins (IL-6 and IL-1 in particular) in the pathogenesis of amyloidosis in a number of autoinflammatory, rheumatic, and autoimmune diseases, including those in periodic disease (PD), has been recently accumulated. Its genetic defect – pirin mutation – gives rise to an alternative innate immune response (phagocytic cell activation) to secrete IL-1 by macrophages and to activate T-helper cells. This causes imbalance in the synthesis of proinflammatory (IL-6, IL-8, and TNF-α) and anti-inflammatory (IL-4, IL-10, and IL-1 receptor antagonist) cytokines. Moreover, the uncontrolled macrophage (monocyte) secretion of a great deal of IL-6 that together with IL-1 is a mediator of the synthesis of the serum amyloid fibril protein precursor SAA by hepatocytes, neutrophils, and fibroblasts plays one of the key roles in the pathogenesis of PD through amyloidosis. With this, IL-6 stimulates the inflammatory process, by enhancing the release of lysosomal enzymes, reactive oxygen species, and eicosanoids (prostaglandins, leukotrienes, thromboxane) from the polymorphic nuclear leukocytes, macrophages, endotheliocytes, and fibroblasts and by augmenting the chemotaxis of macrophages and neutrophils, and the degranulation of the latter, i.e. through its action on the effector cells of inflammation, and prepares the tissue basis for amyloid deposits in this fashion. Thus, the analysis of literary and own materials gives grounds to suggest that pirin mutation is a trigger of the synthesis of IL-1 and IL-6 in PD and their hypersecretion is an initial link of the synthesis of SAA.
About the Author
Z. T. Djndoyan
Therapy Department Two, M. Geratsi Yerevan State Medical University
Russian Federation
Russian Federation
References
1. Саркисян Т., Айрапетян А., Мнджоян М.О. и др. Перспективы ДНК-диагностики наследственной патологии на примере периодической болезни. Мед наука Армении 2001;41(2):31–7.
2. Stojanov S., Kastner D.L. Familial autoinflammatory diseases: genetics, pathogenesis
3. and treatment. Curr Opin Rheumatol 2005;17(5):586–99.
4. Kastner D.L. Hereditary periodic fever syndromes. Hematology Am Soc Hematol Educ Program 2005:74–81.
5. Рамеев В.В., Симонян А.Х., Саркисова И.А. и др. Амилоидоз и наследственные периодические
6. аутовоспалительные заболевания. Клиницист 2008;(2):6–15.
7. Fietta P. Autoinflammatory disease: the hereditary periodic fever syndromes. Acta Biomed 2004;75(2):92–9.
8. Diaz A., Hu C., Kastner D.L. et al. Lipopolysaccharide-induced expression of multiple alternatively spliced MEFV transcripts in human synovial fibroblasts: a prominent splice isoform lacks the C-terminal domain that is highly mutated in familial Mediterranean fever. Arthritis Rheum 2004;50(11):
9. –89.
10. Zarebavani M., Einollahi W., Dashti N. Elevated IL-6 levels in ESRD patients. Int Immunol Meet Abstr 2010;22 (Suppl 1 Pt 2):ii152 (abstr. PP-090-38).
11. Zaleska M., Cakala M., Olszewsky W. Tissue fluid cytokines and growth factors – their role in skin inflammation. Int Immunol Meet Abstr 2010;22(Suppl 1 Pt 2):ii152–3 (abstr. PP-090-41).
12. Direskeneli H. Autoimmunity vs autoinflammation in Behchet’s disease: do we oversimplify a complex disorder? Rheumatology 2006;45(12):1461–5.
13. Mrak R.E., Griffin W.S. Potential inflammatory biomarkers in Alzheimer’s disease. J. Alzheimers Dis 2005;8(4):369–75.
14. Grateau G., Jeru I., Rouaghe S. et al. Amyloidosis and auto-inflammatory syndromes. Curr Drug Targets Inflamm Allergy 2005;4(1):57–65.
15. Guz G., Kanbay M., Ozturk M.A. Current perspectives on familial Mediterranean fever. Curr Opin Infect Dis 2009;22(3):309–15.
16. Haddad J.J. The role of inflammatory cytokines and NF-KB/MAPK signaling pathways in the evolution of familial Mediterranean fever: Current clinical perspectives and potential therapeutic
17. approaches. Cell Immunol 2009;260(1):6–13.
18. Bilginer Y., Roux-Lombard P., Michel Dayer J. et al. Profile of cytokines, growth factors and chemokines during attacks of FMF (Abstract). Pediatric Rheumatology 2008;6(Suppl 1):P207.
19. Touitou I., Sarkisian T., Medlej-Hashim M. et al.; International Study Group for Phenotype-Genotype
20. Correlation in Familial Mediterranean Fever. Country as the primary risk factor for renal amyloidosis in familial Mediterranean fever. Arthritis Rheum 2007;56(5):1706–12.
21. Симонян А.Х., Айвазян А.А., Козловская Л.В., Рамеев В.В. Факторы риска АА-амилоидоза у больных периодической болезнью. Мед вестн Эребуни 2011;1(45):110–15.
22. Тер-Каспарова М.Р. Органопатология периодической болезни. Ереван: Саак Партев, 2002.
23. Balajan B., Yeganyan G., Hovsepyan L.A., Martirosyan N.H. Morphological study of adrenal glands in FMF. Autoinflammation 2010. 6th International Conference in FMF and SAID, Amsterdam, The Nederland, 2010. P. 197–198.
24. Tunca M., Ozdogan H. Molecular and genetic characteristics of hereditary autoinflammatory
25. diseases. Curr Drug Targets Inflamm Allergy 2005;4(1):77–80.
26. Goldbach R.M., Kastner L. Autoinflammation: the prominent role of IL-1 in monogenic autoinflammatory diseases and implications for common illnesses. J Allergy Clin Immunol
27. ;124(6):1141–9; quiz 1150–1.
28. Bagci S., Toy B., Tuzun A. et al. Continuity of cytokine activation in patients with familial Mediterranean fever. Clin Rheumat 2004;23(4):333–7.
29. Karahan Z.C., Ozturk A., Akar E., Akar N. Interleukin-6 (IL-6) – 174 G/C polymorphism in familial Mediterranean fever patients with and without amyloidosis. J Nephrol 2005;18(5):582–4.
30. Шварц В. Регуляция метаболических процессов интерлейкином-6. Цитокины и воспаление 2009; 8(3):3–10.
31. Papanicolaou D.A., Wilder R.L., Manolagas S.C., Chrousos G.P. The pathophysiologic roles of interleukin-6 in human disease. Ann Intern Med 1998;128(2):127–37.
32. Cronstein B.N. Interleukin-6: a key mediator of systemic and local symptoms in rheumatoid arthritis. Bull NYU Hosp Jt Dis 2007;65 Suppl 1:S11–5. 26. Kimura A., Naka T., Kishimoto T. IL-6-dependent and -independent pathways in the development of interleukin-17-producing T helper cells. Proc Natl Acad Sci USA 2007;104(29):12099–104.
33. Лейкок Ф. Основы эндокринологии. М.: Медицина, 2000.
34. МакДермотт М.Т. Секреты эндокринологии. Пер. с англ. В.И. Кандрор. 4-e изд., испр. и доп.
35. М: Бином, 2010.
36. Bilginer Y., Topaloglu R., Alikasifoglu A. et al. Neuroendocrine immune system in familial Mediterranean fever. Turk J Pediatr 2010;52(6):588–93.
37. Sav T., Ozbakir O., Kelestimur F. et al. Adrenal axis functions in patients with familial
38. Mediterranean fever. Clin Rheumatol 2006;25(4):458–61.
39. Овсепян Л.А., Завгородняя А.М., Мартиросян Н.Г. Патогенетическое значение желез внутренней секреции при ПБ. ЕрГМУ им. М. Гераци. Материалы конференции, Ереван, 2007. С. 280–281.
40. Konstantopoulos K. Endocrine function and dysfunction in familial Mediterranean fever. Clin Rheumatol 2006;25(6):885.
41. Арутюнян В.М., Акопян Г.С. Периодическая болезнь (этиопатогенетические и клинические
42. аспекты). М.: Медицинское информационное агентство, 2000.
43. Drenth J.P., van Deuren M., van der Ven-Jongekrijg J. et al. Cytokine activation during attacks of the hyperimmunoglobulinemia D and periodic fever syndrome. Blood 1995;85(12):3586–93.
44. Karageuzyan K., Harutyunian V., Mamiconyan R.S. et al. Evidence of oxidative stress in erythrocyte
45. phospholipid composition in the pathogenesis of FMF (periodic disease).JClin Pathol1996;49(6):453–5.
46. Акопян Г.С., Петросян В.Ф., Чакарян М.Б. и др. Состояние ПОЛ и АОА организма как критерии оценки воспалительного процесса при ПБ. В сб. науч. трудов «Современные проблемы клинической и теоретической медицины». Ереван, 1998. С. 21–24.
47. Tidow N., Chen X., Müller C. et al. Hematopoietic-specific expression of MEFV, the gene mutated in familial Mediterranean fever, and subcellular localization of its corresponding protein, pyrin. Blood 2000;95(4):1451–5.
48. Onat A.M., Oztürk M.A., Ozçakar L. et al. Selective serotonin reuptake inhibitors reduce the attack frequency in familial Mediterranean fever. Tohoku J Exp Med 2007;211(1):9–14.
49. Еганян Г.А. Новая гипотеза о патогенезе приступов периодической болезни и развития амилоидоза. Кровь 2005;1(1):80–5.
50. Dizdar O., Kalyoncu U., Karadag O. et al. Macrophage inflammatory protein 1 alpha: a link between innate immunity and familial Mediterranean fever? Cytokine 2007;37(1):92–5.
51. Айвазян А.А. Периодическая болезнь. Ереван, 1982.
52. Mavragani C.P., Yiannakouris E., Zintzaras E. et al. Analysis of SAA1 gene polymorphisms in the Greek population: rheumatoid arthritis and FMF patients relative to normal controls. Homogeneous distribution and low incidence of AA amyloidosis. Amyloid 2007;14(4):271–5.
Review
For citations:
Djndoyan Z.T. The pathogenesis of amyloidosis in periodic disease: Some aspects. The Clinician. 2012;6(3-4):62-66. (In Russ.) https://doi.org/10.17650/1818-8338-2012-3-4-62-66
Views:
794
Email this article 